142
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Human factors and usability engineering in the development of SMT-101 for the treatment of pulmonary arterial hypertension

, &
Pages 325-333 | Received 04 Aug 2017, Accepted 05 Jan 2018, Published online: 22 Jan 2018

References

  • McLaughlin V, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. J Am Coll Cardiol. 2009;53:1573–1619.
  • Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394–403.
  • Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States. Chest. 2011;139:128–137.
  • Hoeper MM, Gibbs JSR. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014;23:450–457.
  • Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–163.
  • Houtchens J, Martin D, Klinger JR. Diagnosis and management of pulmonary arterial hypertension. Pulm Med. 2011;2011:845864.
  • Barst RJ, Gibb JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S78–84.
  • Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28:1195–1203.
  • Ryerson CJ, Nayar S, Swiston JR, et al. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res. 2010;11:12.
  • Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301.
  • Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000;132:425–434.
  • Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146:449–475.
  • Galie N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903–975.
  • Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:800–804.
  • Sadushi-Koliçi R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant. 2012;31:735–743.
  • Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corp. 2014
  • Kingman MS, Tankersley MA, Lombardi S, et al. Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. J Heart Lung Transplant. 2010;29:841–846.
  • Shaked A, Tenenbaum-Koren E, Atsmon J, et al. In vitro and in vivo performance of a pre-filled, electrochemically-actuated infusion system. Pharm Res. 2015. DOI:10.1007/s11095-015-1765-4
  • U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation. Applying human factors and usability engineering to medical devices. Guidance for industry and Food and Drug Administration staff. February 2016. Available from: http://www.fda.gov/downloads/MedicalDevices/…/UCM259760.pdf [Last accessed November 23, 2016]
  • U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation. List of highest priority devices for human factors review. Draft guidance: industry and Food and Drug Administration staff. February 2016. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM484097.pdf [Last accessed 2016 Nov 29
  • International Electrotechnical Commission. IEC 62366:2007–Medical Devices–Application of Usability Engineering to Medical Devices. 2007. Available from: https://www.iso.org/obp/ui/#iso:std:iec:62366:ed-1:v1:en [Last accessed 2016 Nov 23
  • American National Standards Institute. ANSI/AAMI HE75:2009–human factors engineering–design of medical devices. 2009. Available from: http://webstore.ansi.org/RecordDetail.aspx?sku=ANSI%2FAAMI+HE75+and+ANSI%2FAAMI%2FIEC+62366+Human+Factor+Set [Last accessed 2016 Nov 23]
  • Makary MA, Daniel M. medical error–the third leading cause of death in the US. Br Med J. 2016;353:i2139.
  • Carayon P, Wood KE. Patient safety: the role of human factors and systems engineering. Stud Health Technol Inform. 2010;153:23–46.
  • Rich S. How human factors lead to medical device adverse events. Nursing. 2008;38:62–63.
  • Heinemann L, Fleming GA, Petrie JR, et al. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2015;38:716–722.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.